Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review.
antibody-drug conjugate
clinical trials
head and neck cancer
linkers
payload
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jun 2021
22 Jun 2021
Historique:
received:
26
05
2021
revised:
17
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Antibody-drug conjugates (ADCs) are designed to deliver potent cytotoxic agents into tumor tissues. During the last two decades, a plethora of ADCs have been successfully developed and used for several indications, including hematologic and solid tumors. In this work, we systematically reviewed the progress in ADC development for the treatment of HNC. This review was registered in PROSPERO database. A comprehensive search was conducted following PRISMA guidelines and using PubMed, Scopus and Web of Science database. In total, 19 studies were included. Due to the significant heterogeneity of the outcome measures, meta-analysis was not performed, and data were summarized in tables. HNC results are poorly represented in the cohorts of completed clinical trials; published data are mostly focused on safety evaluation rather than efficacy of ADCs. Although several novel agents against a wide range of different antigens were investigated, showing promising results at a preclinical level, most of the targets reported in this review are not specific for HNC; hence, the development of ADCs tailored for the HNC phenotype could open up new therapeutic perspectives. Moreover, the results from the present systematic review call attention to how limited is the application of current clinical trials in HNC.
Sections du résumé
BACKGROUND
BACKGROUND
Antibody-drug conjugates (ADCs) are designed to deliver potent cytotoxic agents into tumor tissues. During the last two decades, a plethora of ADCs have been successfully developed and used for several indications, including hematologic and solid tumors. In this work, we systematically reviewed the progress in ADC development for the treatment of HNC.
METHODS
METHODS
This review was registered in PROSPERO database. A comprehensive search was conducted following PRISMA guidelines and using PubMed, Scopus and Web of Science database.
RESULTS
RESULTS
In total, 19 studies were included. Due to the significant heterogeneity of the outcome measures, meta-analysis was not performed, and data were summarized in tables. HNC results are poorly represented in the cohorts of completed clinical trials; published data are mostly focused on safety evaluation rather than efficacy of ADCs.
CONCLUSIONS
CONCLUSIONS
Although several novel agents against a wide range of different antigens were investigated, showing promising results at a preclinical level, most of the targets reported in this review are not specific for HNC; hence, the development of ADCs tailored for the HNC phenotype could open up new therapeutic perspectives. Moreover, the results from the present systematic review call attention to how limited is the application of current clinical trials in HNC.
Identifiants
pubmed: 34206707
pii: cancers13133126
doi: 10.3390/cancers13133126
pmc: PMC8269333
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Blood Cancer J. 2020 Oct 23;10(10):106
pubmed: 33097687
Pharmaceuticals (Basel). 2020 Sep 14;13(9):
pubmed: 32937862
Med Sci (Paris). 2009 Dec;25(12):1046-52
pubmed: 20035677
Front Oncol. 2020 Nov 26;10:559596
pubmed: 33324546
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Clin Cancer Res. 2017 May 15;23(10):2516-2527
pubmed: 27780858
Mol Cancer Res. 2017 Dec;15(12):1667-1677
pubmed: 28923838
Biochem Biophys Res Commun. 2013 Jan 4;430(1):150-5
pubmed: 23200832
Eur J Oral Sci. 2004 Oct;112(5):445-51
pubmed: 15458505
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Curr Opin Oncol. 2002 May;14(3):334-42
pubmed: 11981281
Head Neck Pathol. 2021 Jun;15(2):469-478
pubmed: 32959211
J Immunother. 2019 May;42(4):119-125
pubmed: 30933045
Oral Oncol. 2013 Oct;49(10):991-7
pubmed: 23920309
J Clin Oncol. 2006 Jun 10;24(17):2666-72
pubmed: 16763281
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
MAbs. 2021 Jan-Dec;13(1):1860476
pubmed: 33459118
Antibodies (Basel). 2018 Feb 07;7(1):
pubmed: 31544862
BMC Cancer. 2017 Aug 25;17(1):572
pubmed: 28841839
Blood. 2021 May 13;137(19):2634-2645
pubmed: 33211842
Drug Saf. 2019 Feb;42(2):295-314
pubmed: 30649747
Cancer Discov. 2020 May;10(5):688-701
pubmed: 32213540
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549
pubmed: 30859213
Science. 2011 Aug 26;333(6046):1157-60
pubmed: 21798893
Cancer Res. 2009 Apr 1;69(7):3021-31
pubmed: 19318576
Acta Biochim Biophys Sin (Shanghai). 2018 Jun 1;50(6):567-578
pubmed: 29718150
Cancer Lett. 2006 Jul 28;239(1):129-35
pubmed: 16198049
Cancer Res. 2018 Jul 15;78(14):4059-4072
pubmed: 29764866
BMC Med Res Methodol. 2012 Jul 30;12:111
pubmed: 22846171
Chem Pharm Bull (Tokyo). 2019;67(3):173-185
pubmed: 30827997
BMC Cancer. 2014 Jan 13;14:15
pubmed: 24410905
J Oral Pathol Med. 2020 Nov;49(10):1019-1029
pubmed: 32740991
Mol Cancer Ther. 2018 Nov;17(11):2412-2426
pubmed: 30126944
Cancer Chemother Pharmacol. 2017 May;79(5):915-922
pubmed: 28349167
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Acta Oncol. 2016 Sep - Oct;55(9-10):1084-1090
pubmed: 27550781
J Dent Hyg. 2001 Winter;75(1):50-63
pubmed: 11314227
Clin Cancer Res. 2004 Aug 1;10(15):5264-70
pubmed: 15297430
Exp Mol Pathol. 2017 Feb;102(1):59-64
pubmed: 28062212
J Drug Target. 2003 Feb;11(2):101-7
pubmed: 12881196
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Mol Cancer Ther. 2012 Mar;11(3):594-603
pubmed: 22169768
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
J Clin Oncol. 2019 May 1;37(13):1102-1110
pubmed: 30860949
Anticancer Res. 2015 Oct;35(10):5519-24
pubmed: 26408719
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Neurochem. 2003 Feb;84(3):557-65
pubmed: 12558975
Mol Cancer Ther. 2020 Sep 23;:
pubmed: 32967924
Jpn J Clin Oncol. 2013 May;43(5):524-31
pubmed: 23479384
Cancer Res. 2017 Mar 1;77(5):1188-1199
pubmed: 28031227
Drugs. 2001;61(9):1317-22; discussion 1323-4
pubmed: 11511025
Drugs. 2014 Apr;74(6):675-86
pubmed: 24659374
Front Oncol. 2021 Mar 05;11:596290
pubmed: 33747915
Oncol Lett. 2013 May;5(5):1694-1698
pubmed: 23760364
Expert Opin Biol Ther. 2019 Jun;19(6):501-508
pubmed: 31045462
Mol Cancer Ther. 2016 Nov;15(11):2698-2708
pubmed: 27582525
Clin Cancer Res. 2008 Jul 15;14(14):4584-92
pubmed: 18628473
Int J Oncol. 2007 Apr;30(4):927-35
pubmed: 17332932
Cell. 2015 Sep 24;163(1):39-53
pubmed: 26406370
Oral Oncol. 2014 Nov;50(11):1041-8
pubmed: 25176576
Int J Oncol. 2011 May;38(5):1219-26
pubmed: 21344157
Oncotarget. 2018 Sep 11;9(71):33446-33458
pubmed: 30323890
Cancer Res. 2011 Jun 15;71(12):4236-46
pubmed: 21540235
Cancer Biother Radiopharm. 2011 Oct;26(5):593-601
pubmed: 21834651
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19024-9
pubmed: 22065749
Clin Cancer Res. 2001 Nov;7(11):3314-24
pubmed: 11705842
Int J Oral Sci. 2020 May 28;12(1):16
pubmed: 32461587
Oral Oncol. 2008 Sep;44(9):823-9
pubmed: 18203652
Curr Treat Options Oncol. 2012 Mar;13(1):35-46
pubmed: 22252884
Drugs. 2017 Sep;77(14):1603-1610
pubmed: 28819740
Clin Epidemiol. 2014 Oct 10;6:359-68
pubmed: 25336990
Mol Cancer Ther. 2020 Oct;19(10):2117-2125
pubmed: 32847977
Expert Rev Anticancer Ther. 2020 Jan;20(1):17-29
pubmed: 31899993
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Jpn J Clin Oncol. 2013 May;43(5):476-82
pubmed: 23479383
Anticancer Res. 2002 Jul-Aug;22(4):1977-82
pubmed: 12174873
Int J Surg Pathol. 2021 Jun;29(4):368-377
pubmed: 33289434
Oncotarget. 2015 Sep 29;6(29):28164-72
pubmed: 26172299
Oral Dis. 2020 Jan;26(1):3-5
pubmed: 31557358
Cancer. 2020 Jul 15;126(14):3237-3243
pubmed: 32365226
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Lancet Oncol. 2019 Mar;20(3):383-393
pubmed: 30745090
Cancers Head Neck. 2020 Apr 6;5:5
pubmed: 32280512
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Cancer. 2017 Oct 1;123(19):3843-3854
pubmed: 28558150
J Control Release. 2016 May 10;229:93-105
pubmed: 26988602
Cancers (Basel). 2020 Mar 20;12(3):
pubmed: 32245016
Clin Cancer Res. 2002 Jan;8(1):281-6
pubmed: 11801570
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
Ther Clin Risk Manag. 2007 Oct;3(5):871-6
pubmed: 18473010
Oncologist. 2010;15 Suppl 3:3-7
pubmed: 21036882
Eur J Nucl Med Mol Imaging. 2021 May 29;:
pubmed: 34050405
Int Immunol. 2021 Jan 1;33(1):7-15
pubmed: 32496557
Crit Rev Oncol Hematol. 2006 Jan;57(1):25-43
pubmed: 16207530
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Br J Clin Pharmacol. 2016 Sep;82(3):696-705
pubmed: 27115790
Cancer Res. 2016 May 15;76(10):3003-13
pubmed: 27013195
Oncotarget. 2017 Apr 11;8(15):24457-24468
pubmed: 28160550
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Invest New Drugs. 2020 Oct;38(5):1483-1494
pubmed: 32189093
Cancer. 2008 Jun 15;112(12):2635-45
pubmed: 18442098
Cells. 2020 Sep 15;9(9):
pubmed: 32942747
J Signal Transduct. 2011;2011:982879
pubmed: 21776391
J Oral Pathol Med. 2009 Aug;38(7):572-9
pubmed: 19549112
BMC Cancer. 2006 Oct 25;6:253
pubmed: 17064405
Mol Oncol. 2020 Jan;14(1):54-68
pubmed: 31736230
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
ACS Med Chem Lett. 2016 May 24;7(11):983-987
pubmed: 27882195
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Curr Cancer Drug Targets. 2019;19(1):65-73
pubmed: 28460618
Oncol Lett. 2020 Apr;19(4):2809-2816
pubmed: 32218834
J Control Release. 2018 Sep 28;286:289-300
pubmed: 30081143
Int J Surg. 2010;8(5):336-41
pubmed: 20171303